Trial · NCT03446612
Results by group500
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 500
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42) | Daprodustat | 2 umol/min | 0.7426 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42) | Darbepoetin Alfa | 2 umol/min | 0.9024 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42) | Daprodustat | 8 umol/min | 0.4975 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42) | Darbepoetin Alfa | 8 umol/min | 0.8690 | Standard Deviation NA | Ratio |
| Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA | Daprodustat | 2 umol/min | 1.1508 | Standard Deviation NA | umol/min |
| Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA | Darbepoetin Alfa | 2 umol/min | 0.3558 | Standard Deviation NA | umol/min |
| Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA | Daprodustat | 8 umol/min | 0.0974 | Standard Deviation NA | umol/min |
| Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA | Darbepoetin Alfa | 8 umol/min | 0.0399 | Standard Deviation NA | umol/min |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 Versus (vs) Day 1 in Participants Treated With Daprodustat | Daprodustat | 7.5 ug/min, n=2 | 0.2744 | Standard Deviation 0.91996 | Ratio |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 Versus (vs) Day 1 in Participants Treated With Daprodustat | Daprodustat | 15 ug/min, n=1 | -0.8503 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 Versus (vs) Day 1 in Participants Treated With Daprodustat | Daprodustat | 30 ug/min, n=1 | 0.5482 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat | Daprodustat | 3 ug/min | 0.1618 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat | Daprodustat | 10 ug/min | 3.2651 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat | Daprodustat | 2 umol/min | -0.3896 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat | Daprodustat | 8 umol/min | -0.7216 | Standard Deviation NA | Ratio |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Darbepoetin Alfa | 7.5 ug/min | -2.0376 | Standard Deviation 0.63291 | Ratio |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Darbepoetin Alfa | 15 ug/min | -1.4559 | Standard Deviation 0.01558 | Ratio |
| Change in FBF Ratio in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Darbepoetin Alfa | 30 ug/min | -1.0652 | Standard Deviation 1.56389 | Ratio |
| Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Darbepoetin Alfa | 3 ug/min | -0.7503 | Standard Deviation 0.26692 | Ratio |
| Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Darbepoetin Alfa | 10 ug/min | -1.2405 | Standard Deviation 0.15366 | Ratio |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03446612/results?page=2